Acticor Biotech Summary
Acticor Biotech is a clinical stage biotech company, developing an innovative drug for the treatment of acute thrombotic diseases, including the acute phase of ischemic stroke.
Acticor Biotech is a spin-off company from Inserm (French National Institute of Health and Medical Research) founded in November 2013. The Headquarter is located in the Inserm U1148 building inside the Bichat Hospital in Paris.
Acticor Biotech is developing glenzocimab (ACT017), a humanized Antibody Fragment (Fab). The therapeutic candidate is directed against a novel target of major interest, the platelet glycoprotein VI (GPVI), and inhibits its action. Evidence of antithrombotic efficacy of glenzocimab and safety of inhibition of GPVI have been established both ex vivo and in vivo. The target is involved in the growth of the thrombus, but not in physiological haemostasis. This limits the bleeding risk associated with its inhibition.
In February 2018, Acticor Biotech announced the completion of its phase I clinical trial in healthy volunteers. The primary endpoint assessing safety and tolerability was achieved with no serious adverse event reported at any of the doses tested (Voors-Pette et al. ATVB 2019).
Glenzocimab is currently being evaluated in a phase 2a clinical trial (ACTIMIS NCT 038030037), an international multi-center clinical trial, on top of the standard of care in patients with acute ischemic stroke.
Since 2015, Acticor Biotech received the label EIP by Medicen (Innovative Enterprise) and has been recognized by Genopole.
In 2016, Acticor Biotech was laureate of the Concours Mondial d’Innovation (World Innovation Contest) and was also laureate of the Concours Tremplin d’Entreprises du Sénat (national contest for innovative enterprises).
In 2017, Acticor Biotech was laureate of the Concours Mondial d’Innovation phase II.
In 2020, Acticor Biotech Joined the First French Tech 120
French Tech 120
Lauréat 2017 du Concours Mondial de l’Innovation phase II
Lauréat 2016 du Concours Mondial de l’Innovation
Lauréat 2016 du Concours Tremplin d’Entreprise du Sénat